Welcome to Paid Research Studies




  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Lymphoblastic Lymphoma;   Diffuse Large B-cell Lymphoma;   Burkitt Lymphoma/Leukemia
    Interventions:   Drug: Clofarabine;   Drug: Mitoxantrone
    Sponsor:   New York Medical College
    Recruiting

  • Conditions:   Neoplasms;   Myelodysplastic Syndromes;   Lymphomas
    Intervention:   Drug: Bortezomib plus Clofarabine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory T-Cell Non-Hodgkin Lymphoma
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Clofarabine;   Drug: Gemcitabine Hydrochloride;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Biological: Rituximab;   Drug: Tacrolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Bilineal Leukemia;   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Mixed Phenotype Acute Leukemia;   Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified;   Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified;   Recurrent Mixed Phenotype Acute Leukemia
    Interventions:   Drug: Clofarabine;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Idarubicin;   Biological: Rituximab;   Drug: Sorafenib Tosylate;   Drug: Vincristine Sulfate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Non-Malignant Hematologic Disorders
    Interventions:   Drug: Melphalan;   Drug: Thiotepa;   Drug: Clofarabine;   Drug: Fludarabine;   Drug: Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®);   Procedure: CliniMACS reagents
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Burkitt Leukemia;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Burkitt Leukemia;   Recurrent Burkitt Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   Refractory Acute Lymphoblastic Leukemia;   Refractory Burkitt Leukemia;   Refractory Burkitt Lymphoma;   Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   Refractory Lymphoblastic Lymphoma
    Interventions:   Drug: Bortezomib;   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Etoposide;   Biological: Ofatumumab;   Biological: Pegfilgrastim;   Biological: Rituximab;   Drug: Vincristine Sulfate Liposome
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
    Interventions:   Radiation: total body irradiation;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Melphalan;   Drug: Fludarabine;   Drug: Clofarabine;   Procedure: (CliniMACS) T-cell depleted PBSC Transplant
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Acute Lymphoid Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Chronic Myeloid Leukemia (CML);   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
    Interventions:   Radiation: Hyperfractionated total body irradiation;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Clofarabine;   Procedure: HPC(A) stem cell allograft;   Drug: Rituximab;   Device: Rabbit antithymocyte globulin
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Acute Myeloid Leukemia With Variant MLL Translocations;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Chemotherapy-Related Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   ISS Stage II Plasma Cell Myeloma;   ISS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Gene Mutation;   Myelodysplastic/Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Biological: Allogeneic Natural Killer Cell Line NK-92;   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Biological: Rituximab;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Langerhans Cell Histiocytosis
    Intervention:   Drug: Clofarabine
    Sponsors:   Dana-Farber Cancer Institute;   Sanofi;   St. Baldrick's Foundation;   Cookies for Kids' Cancer;   North American Consortium for Histiocytosis
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Lymphoma
    Interventions:   Drug: Prednisone;   Drug: Vincristine;   Drug: Daunorubicin;   Drug: Pegaspargase;   Drug: Erwinase®;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Mercaptopurine;   Drug: Dasatinib;   Drug: Methotrexate;   Drug: Blinatumomab;   Drug: Ruxolitinib;   Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Clofarabine;   Drug: Vorinostat;   Drug: Idarubicin;   Drug: Nelarabine
    Sponsors:   St. Jude Children's Research Hospital;   Bristol-Myers Squibb;   Incyte Corporation;   Shire
    Recruiting

  • Condition:   Malignant Melanoma
    Intervention:   Drug: [18F] CFA
    Sponsors:   Jonsson Comprehensive Cancer Center;   Tesaro, Inc.;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Urothelial Carcinoma;   Bladder Cancer;   Urinary Bladder Neoplasms
    Interventions:   Drug: 75 approved agents;   Other: COXEN
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Leukemia, Acute;   MDS
    Interventions:   Procedure: Bone Marrow or Peripheral Blood Graft (BMT);   Other: Cancer-directed Therapy or Best Supportive Care;   Diagnostic Test: Frailty Assessment
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting

  • Conditions:   Acute Leukemia of Ambiguous Lineage;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory Childhood Acute Lymphoblastic Leukemia
    Interventions:   Other: Chemosensitivity Assay;   Other: Cytology Specimen Collection Procedure;   Genetic: Gene Expression Analysis;   Genetic: Genetic Variation Analysis;   Drug: In Vitro Sensitivity-Directed Chemotherapy
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Leukemia, Acute Myeloid;   Myeloid Leukemia, Acute;   Leukemia, Myeloid, Acute;   Acute Myelogenous Leukemia;   Leukemia, Acute Myelogenous;   Myelogenous Leukemia, Acute;   AML;   Bone Marrow Transplant
    Interventions:   Drug: Iomab-B;   Drug: Conventional Care;   Procedure: HCT
    Sponsor:   Actinium Pharmaceuticals
    Recruiting